AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from 2027, including Novo Nordisk's mega bestseller Ozempic which will see a 71% discount to its list price.
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk manufacturing expansion, growth plans, next-gen therapies, and more.
AstraZeneca to invest $2 billion as part of US manufacturing push
AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 billion plan to expand manufacturing and research capabilities in the U.S. by 2030.
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes
Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don't work equally well in patients with diabetes, a study from India found.
AstraZeneca leans on its pipeline as $80bn revenue target comes into view
It is not every day that a company makes a habit of turning in positive clinical results at a pace that would make even the most seasoned drug developer blink. Yet AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has managed just that this year, and Shore Capital thinks the torrent of data is enough to justify a fresh uplift to forecasts, even if the real strategic test lies a little further down the road.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca hits record high, cements lead as UK's biggest stock
Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's position as the largest UK-listed stock by market value.
AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript
AstraZeneca PLC ( AZN ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Andrew Barnett - Head of Investor Relations Pascal Soriot - CEO & Executive Director Aradhana Sarin - CFO & Executive Director David Fredrickson - Executive Vice-President of Oncology Haematology Business Unit Susan Galbraith - Executive Vice President of Oncology R&D Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D Marc Dunoyer - CEO of Alexion & Chief Strategy Officer Conference Call Participants Michael Leuchten - Jefferies LLC, Research Division Sarita Kapila - Morgan Stanley, Research Division Justin Smith Sachin Jain - BofA Securities, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Peter Verdult - BNP Paribas, Research Division Mattias Häggblom - Handelsbanken Capital Markets AB, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Matthew Weston - UBS Investment Bank, Research Division Steve Scala - TD Cowen, Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division Gonzalo Artiach Castanon - Danske Bank A/S, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Presentation Operator Good afternoon, and welcome to AstraZeneca's 9 months and Q3 2025 webinar for investors and analysts.
AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)
The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. AstraZeneca's financials remain robust, with double-digit revenue and EPS growth, but Q4 2025 is expected to show slower or even negative EPS growth. Risks could also stem from U.S. pricing pressures and potentially unresolved tax issues in China. Additionally, stretched valuations and limited near-term upside, prompt a Hold rating.
AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform
AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.
AstraZeneca climbs to net all-time high after US deal reassurance
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted what analysts called a very solid set of third-quarter results, but the shares barely moved in early morning trading as the City waited for more details on the analyst call. In afternoon trading, shares in the giant drugmaker jumped over 4% to a new all time high above 12,990p.
